Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program

被引:509
作者
Fe, Rongwei [1 ]
Gartlehner, Gerald [2 ]
Grant, Mark [3 ]
Shamliyan, Tatyana [7 ]
Sedrakyan, Art [5 ]
Wilt, Timothy J. [4 ,6 ]
Griffith, Lauren [8 ]
Oremus, Mark [8 ]
Raina, Parminder [8 ]
Ismaila, Afisi [8 ]
Santaguida, Pasqualina [8 ]
Lau, Joseph [9 ,10 ]
Trikalinos, Thomas A. [9 ,10 ]
机构
[1] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA
[2] Danube Univ, Dept Evidence Based Med & Clin Epidemiol, A-3500 Krems, Austria
[3] Blue Cross Blue Shield Assoc, Technol Evaluat Ctr, Chicago, IL USA
[4] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[5] Agcy Healthcare Res & Qual, Ctr Outcomes & Evidence, Rockville, MD USA
[6] Minnesota Evidence Based Practice Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA
[7] Univ Minnesota, Div Hlth Policy & Management, Minnesota Evidence Based Practice Ctr, Minneapolis, MN 55455 USA
[8] McMaster Univ, Dept Clin Epidemiol & Biostat, McMaster Evidence Based Practice Ctr, Hamilton, ON, Canada
[9] Tufts Med Ctr, Tufts Evidence Based Practice Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA
[10] Tufts Med Ctr, Ctr Clin Evidence Synth, Inst Clin Res & Hlth Policy Studies, Boston, MA USA
基金
美国医疗保健研究与质量局;
关键词
Meta-analysis; Indirect comparison; Effect measure; Fixed/random effects model; Heterogeneity; Mixed design; RANDOM-EFFECTS METAANALYSIS; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; TREATMENT EFFICACY; HETEROGENEITY; ROSIGLITAZONE; NUMBER; EVENT; RISK; INCONSISTENCY;
D O I
10.1016/j.jclinepi.2010.08.010
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: This article is to establish recommendations for conducting quantitative synthesis, or meta-analysis, using study-level data in comparative effectiveness reviews (CERs) for the Evidence-based Practice Center (EPC) program of the Agency for Healthcare Research and Quality. Study Design and Setting: We focused on recurrent issues in the EPC program and the recommendations were developed using group discussion and consensus based on current knowledge in the literature. Results: We first discussed considerations for deciding whether to combine studies, followed by discussions on indirect comparison and incorporation of indirect evidence. Then, we described our recommendations on choosing effect measures and statistical models, giving special attention to combining studies with rare events; and on testing and exploring heterogeneity. Finally, we briefly presented recommendations on combining studies of mixed design and on sensitivity analysis. Conclusion: Quantitative synthesis should be conducted in a transparent and consistent way. Inclusion of multiple alternative interventions in CERs increases the complexity of quantitative synthesis, whereas the basic issues in quantitative synthesis remain crucial considerations in quantitative synthesis for a CER. We will cover more issues in future versions and update and improve recommendations with the accumulation of new research to advance the goal for transparency and consistency. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1187 / 1197
页数:11
相关论文
共 66 条
[51]  
2-8
[52]  
Prevost TC, 2000, STAT MED, V19, P3359, DOI 10.1002/1097-0258(20001230)19:24<3359::AID-SIM710>3.0.CO
[53]  
2-N
[54]   An assessment of the use of the continuity correction for sparse data in meta-analysis [J].
Sankey, SS ;
Weissfeld, LA ;
Fine, MJ ;
Kapoor, W .
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 1996, 25 (04) :1031-1056
[55]  
Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO
[56]  
2-6
[57]   Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors [J].
Schmid, CH ;
Stark, PC ;
Berlin, JA ;
Landais, P ;
Lau, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (07) :683-697
[58]   'Unqualified success' and 'unmitigated failure': Number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events [J].
Schulzer, M ;
Mancini, GBJ .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1996, 25 (04) :704-712
[59]   Fixed vs random effects meta-analysis in rare event studies:: The Rosiglitazone link with myocardial infarction and cardiac death [J].
Shuster, Jonathan J. ;
Jones, Lynn S. ;
Salmon, Daniel A. .
STATISTICS IN MEDICINE, 2007, 26 (24) :4375-4385
[60]   AHRQ Series Paper 1: Comparing medical interventions: AHRQ and the Effective Health-Care Program [J].
Slutsky, Jean ;
Atkins, David ;
Chang, Stephanie ;
Sharp, Beth A. Collins .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (05) :481-483